CL2019000061A1 - Anticuerpo para anti-claudin 18a2 y su utilización. - Google Patents

Anticuerpo para anti-claudin 18a2 y su utilización.

Info

Publication number
CL2019000061A1
CL2019000061A1 CL2019000061A CL2019000061A CL2019000061A1 CL 2019000061 A1 CL2019000061 A1 CL 2019000061A1 CL 2019000061 A CL2019000061 A CL 2019000061A CL 2019000061 A CL2019000061 A CL 2019000061A CL 2019000061 A1 CL2019000061 A1 CL 2019000061A1
Authority
CL
Chile
Prior art keywords
claudin
antibody
points
methods
invention consists
Prior art date
Application number
CL2019000061A
Other languages
English (en)
Inventor
Wang Peng
Jiang Hua
Yang Linlin
SHI Zhimim
Wang Huamao
Li Zonghai
Original Assignee
Carsgen Therapeutics Co Ltd
Shanghai Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/zh
Application filed by Carsgen Therapeutics Co Ltd, Shanghai Cancer Inst filed Critical Carsgen Therapeutics Co Ltd
Publication of CL2019000061A1 publication Critical patent/CL2019000061A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

LA PRESENTE INVENCIÓN CONSISTE EN UN ANTICUERPO PARA ANTI-CLAUDIN 18A2 Y UNA CÉLULA EFECTORA INMUNE QUE APUNTA A CLAUDIN 18A2. TAMBIÉN SE PROPORCIONAN MÉTODOS PARA INDUCIR LA MUERTE CELULAR Y TRATAR TUMORES.
CL2019000061A 2016-07-08 2019-01-08 Anticuerpo para anti-claudin 18a2 y su utilización. CL2019000061A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610536449 2016-07-08
PCT/CN2017/082024 WO2017186121A1 (zh) 2016-04-26 2017-04-26 一种改善免疫应答细胞功能的方法

Publications (1)

Publication Number Publication Date
CL2019000061A1 true CL2019000061A1 (es) 2019-05-03

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000061A CL2019000061A1 (es) 2016-07-08 2019-01-08 Anticuerpo para anti-claudin 18a2 y su utilización.

Country Status (13)

Country Link
US (2) US11111295B2 (es)
EP (1) EP3483182B1 (es)
JP (1) JP7587921B2 (es)
KR (1) KR102723896B1 (es)
CN (1) CN109790222B (es)
AU (1) AU2017294276B2 (es)
BR (1) BR112019000327A8 (es)
CA (1) CA3030257A1 (es)
CL (1) CL2019000061A1 (es)
ES (1) ES2979068T3 (es)
IL (1) IL264144B2 (es)
SG (1) SG11201900171QA (es)
WO (1) WO2018006882A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
JP2021512875A (ja) 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 細胞免疫療法の組み合わせ
MX2020009326A (es) 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
US12186343B2 (en) * 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
CA3087423A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
US20220127570A1 (en) 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
JP2021523743A (ja) 2018-05-15 2021-09-09 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 遺伝子操作された細胞及びその応用
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
CN112930199B (zh) 2018-07-24 2024-08-13 恺兴生命科技(上海)有限公司 免疫效应细胞治疗肿瘤的方法
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
CN110862454B (zh) * 2018-08-27 2022-12-30 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途
EP3858384A4 (en) * 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
EP3892333A4 (en) 2018-12-07 2022-11-30 CRAGE medical Co., Limited ANTI-TUMOR POLYIMMUNOTHERAPY
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
MX2021007939A (es) * 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Porciones de union a claudina 18.2 y usos de estas.
KR20210109520A (ko) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
KR20210126008A (ko) * 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
CN114106183B (zh) * 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
JP7840511B2 (ja) * 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン１８抗体及びそれらの使用の方法
JP2022523749A (ja) * 2019-02-01 2022-04-26 クレージュ メディカル カンパニー，リミテッド Ｔｃｒ融合タンパク質およびｔｃｒ融合タンパク質を発現する細胞
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
TW202042824A (zh) 2019-03-27 2020-12-01 賓夕法尼亞大學董事會 Tn-MUC1嵌合抗原受體（CAR）T細胞療法
WO2020205331A1 (en) * 2019-03-29 2020-10-08 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
MX2021011489A (es) 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
US12655199B2 (en) 2019-04-19 2026-06-16 Keymed Biosciences Co., Ltd. Tumor therapeutic agent and use thereof
BR112021023024A2 (pt) * 2019-05-16 2022-01-25 Qilu Pharmaceutical Co Ltd Anticorpo contra claudina 18a2 e uso do mesmo
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CA3141504A1 (en) 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
BR112021023897A2 (pt) * 2019-05-30 2022-01-25 Shandong Boan Biotechnology Co Ltd Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
CN114364701A (zh) * 2019-07-17 2022-04-15 加利福尼亚大学董事会 密封蛋白18抗体和治疗癌症的方法
US11261259B2 (en) * 2019-08-12 2022-03-01 I-Mab Biopharma Us Limited Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
CN112574307B (zh) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
AU2020378502A1 (en) * 2019-11-05 2022-06-16 LaNova Medicines Limited Antibody-drug conjugates targeting claudin 18.2
US20230000918A1 (en) * 2019-11-29 2023-01-05 Suzhou Nova Therapeutics Co. Ltd Chimeric antigen receptors, compositions and applications thereof
JP7641967B2 (ja) 2019-12-06 2025-03-07 ソティオ バイオテック エイ．エス． ヒト化ｃｌｄｎ１８．２抗体
BR112022012327A2 (pt) 2019-12-23 2022-10-18 Sotio Biotech A S Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira
AU2021204861B2 (en) * 2020-01-03 2024-10-17 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
AU2021218927B2 (en) * 2020-02-10 2024-12-19 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
EP4110820A4 (en) * 2020-02-25 2024-03-27 Gensun Biopharma Inc. Trispecific t cell engagers
CR20220580A (es) * 2020-05-15 2023-04-11 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CA3178855A1 (en) * 2020-06-19 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 antibody and use thereof
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
WO2022011531A1 (zh) * 2020-07-14 2022-01-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CN116194125A (zh) 2020-08-07 2023-05-30 克莱格医学有限公司 工程化改造的细胞以及工程化改造细胞的方法
EP4222174A4 (en) * 2020-09-30 2025-02-12 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
US20240181055A1 (en) * 2021-04-08 2024-06-06 Crage Medical Co., Limited Cellular immunotherapy use
WO2022218375A1 (zh) * 2021-04-15 2022-10-20 克莱格医学有限公司 嵌合t细胞受体及其应用
EP4335873A4 (en) 2021-05-08 2025-03-19 RemeGen Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
WO2023274303A1 (zh) 2021-06-29 2023-01-05 科济生物医药（上海）有限公司 调控细胞生理活动的嵌合多肽
CN114907482B (zh) * 2021-09-03 2023-02-14 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
WO2023078386A1 (zh) * 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN119677781A (zh) * 2022-05-06 2025-03-21 上海先博生物科技有限公司 靶向cldn18.2的嵌合抗原t细胞受体及其应用
CN120484126B (zh) * 2022-07-28 2025-11-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
EP4604966A1 (en) * 2022-10-20 2025-08-27 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
JP2025535445A (ja) * 2022-10-20 2025-10-24 マイクロ クリスパー プライベート リミテッド 免疫療法におけるサイトカイン放出症候群の軽減
WO2024084520A1 (en) * 2022-10-20 2024-04-25 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
WO2024084518A1 (en) * 2022-10-20 2024-04-25 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
KR20250089537A (ko) * 2022-10-20 2025-06-18 마이크로크리스퍼 피브이티 리미티드 면역치료에서의 사이토카인 방출 증후군 감소
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026020041A1 (en) * 2024-07-17 2026-01-22 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US20260159608A1 (en) * 2024-10-25 2026-06-11 Antharis Therapeutics Inc. Flt3-binding antibodies and methods of use thereof
CN120005046B (zh) * 2025-04-18 2025-09-02 深锐(天津)生物医学有限公司 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白
CN121517573A (zh) * 2025-11-27 2026-02-13 无锡傲锐东源生物科技有限公司 一种VB12夹心法抗体mAb10或其抗原结合片段、及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN120329449A (zh) 2014-07-17 2025-07-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
PE20181302A1 (es) 2015-12-04 2018-08-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-claudina y sus metodos de uso
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
US12186343B2 (en) * 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
EP3858384A4 (en) * 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
KR20210126008A (ko) * 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
WO2022033483A1 (zh) * 2020-08-10 2022-02-17 佧珐药业有限公司 多功能的免疫效应细胞及其应用

Also Published As

Publication number Publication date
BR112019000327A8 (pt) 2022-10-18
ES2979068T3 (es) 2024-09-24
KR102723896B1 (ko) 2024-11-01
JP7587921B2 (ja) 2024-11-21
IL264144B1 (en) 2023-07-01
JP2019531084A (ja) 2019-10-31
US20190233511A1 (en) 2019-08-01
CN109790222A (zh) 2019-05-21
IL264144B2 (en) 2023-11-01
AU2017294276A1 (en) 2019-02-28
KR20190038564A (ko) 2019-04-08
NZ750420A (en) 2025-06-27
RU2019101430A3 (es) 2021-05-17
SG11201900171QA (en) 2019-02-27
IL264144A (en) 2019-02-28
RU2019101430A (ru) 2020-08-10
CA3030257A1 (en) 2018-01-11
US11111295B2 (en) 2021-09-07
CN109790222B (zh) 2022-03-15
EP3483182A4 (en) 2020-07-29
BR112019000327A2 (pt) 2019-08-13
WO2018006882A1 (zh) 2018-01-11
EP3483182A1 (en) 2019-05-15
US20220185880A1 (en) 2022-06-16
EP3483182B1 (en) 2024-05-08
AU2017294276B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
BR112019012342A2 (pt) anticorpos il-11
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
CO2017010618A2 (es) Anticuerpos contra icos
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
MX391249B (es) Anticuerpos anti-muc16 y sus usos.
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20190271A (es) Anticuerpos antitau y métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IL269157A (en) Compositions and methods for treating cancer